These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21511293)

  • 21. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
    Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
    Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review).
    Hill B; Kyprianou N
    Oncol Rep; 2002; 9(6):1151-6. PubMed ID: 12375010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
    Gan L; Wang J; Xu H; Yang X
    Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
    Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
    Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
    Gomez LA; de Las Pozas A; Perez-Stable C
    Mol Cancer Ther; 2006 May; 5(5):1216-26. PubMed ID: 16731754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
    Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M
    Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    Molina A; Belldegrun A
    J Urol; 2011 Mar; 185(3):787-94. PubMed ID: 21239012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
    J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.
    Thompson VC; Morris TG; Cochrane DR; Cavanagh J; Wafa LA; Hamilton T; Wang S; Fazli L; Gleave ME; Nelson CC
    Prostate; 2006 Dec; 66(16):1698-709. PubMed ID: 16998820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
    Pootrakul L; Datar RH; Shi SR; Cai J; Hawes D; Groshen SG; Lee AS; Cote RJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5987-93. PubMed ID: 17062670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.